documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
1,711,198 rows sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
These facets timed out: agency_id, document_type
posted_year >30
- 2018 106,690
- 2016 98,713
- 2019 91,918
- 2015 80,499
- 2024 78,228
- 2023 73,203
- 2017 72,886
- 2021 71,789
- 2022 71,318
- 2020 69,829
- 2006 68,985
- 2014 65,338
- 2007 63,922
- 2011 61,511
- 2025 61,376
- 2013 61,338
- 2012 60,059
- 2010 56,532
- 2008 55,828
- 2009 54,066
- 2004 47,970
- 2005 47,206
- 2003 34,977
- 2002 28,411
- 2001 20,449
- 2000 19,990
- 2026 18,576
- 1999 17,091
- 1998 14,407
- 1995 13,108
- …
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DOT-OST-2002-12555-0308 | DOT | None DOT-OST-2002-12555 | American Airlines, Inc. | Other | Correspondence | 2026-12-13T05:00:00Z | 2026 | 12 | 2025-10-28T04:00:00Z | 2026-02-14T13:14:34Z | 1 | 0 | 09000064b9056fb2 | ||
| USDA_FRDOC_0001-3307 | USDA | Recently Posted USDA Rules and Notices. USDA_FRDOC_0001 | Modified Organisms Subject to the Plant Protection Act | Proposed Rule | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-06-16T03:59:59Z | 2026-05-16T09:00:19Z | 2026-09833 | 1 | 0 | 09000064b92da9bf | |
| FWS-HQ-IA-2026-0298-0014 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Minnesota Zoo, Apple Valley, MN; Permit No. PER26188753 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:03Z | 0 | 0 | 09000064b92d95a4 | ||||
| FWS-R5-FAC-2026-1684-0006 | FWS | Agency Information Collection Activities; Submission to the Office of Management and Budget; Horseshoe Crab and Cooperative Fish Tagging Programs FWS-R5-FAC-2026-1684 | FWS Form 3-2494 Snakehead Recapture Data Rev 07-2017 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:48:15Z | 0 | 0 | 09000064b92d9027 | ||||
| FWS-HQ-IA-2026-0298-0001 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Foreign Endangered Species; Receipt of Permit Applications | Notice | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-06-16T03:59:59Z | 2026-05-15T16:53:53Z | 2026-09807 | 1 | 0 | 09000064b92db145 | |
| FWS-HQ-IA-2026-0298-0015 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Turtle Survival Alliance, North Charleston, SC; Permit No. PER27332264 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:03Z | 0 | 0 | 09000064b92d95a5 | ||||
| FWS-HQ-IA-2026-0298-0016 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: John Ball Zoo, Grand Rapids, MN; Permit No. PER27754098 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:04Z | 0 | 0 | 09000064b92d95a6 | ||||
| FWS-R5-FAC-2026-1684-0002 | FWS | Agency Information Collection Activities; Submission to the Office of Management and Budget; Horseshoe Crab and Cooperative Fish Tagging Programs FWS-R5-FAC-2026-1684 | FWS Form 3-2495 Striped Bass Recapture Data Rev 07-2017 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:48:09Z | 0 | 0 | 09000064b92d9023 | ||||
| FWS-R5-FAC-2026-1684-0003 | FWS | Agency Information Collection Activities; Submission to the Office of Management and Budget; Horseshoe Crab and Cooperative Fish Tagging Programs FWS-R5-FAC-2026-1684 | FWS Form 3-2496 Sturgeon Recapture Data Rev 07-2017 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:48:11Z | 0 | 0 | 09000064b92d9024 | ||||
| FWS-R5-FAC-2026-1684-0007 | FWS | Agency Information Collection Activities; Submission to the Office of Management and Budget; Horseshoe Crab and Cooperative Fish Tagging Programs FWS-R5-FAC-2026-1684 | FWS Form 3-2311 Horseshoe Crab Tagging Report Rev 07-2017 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:48:16Z | 0 | 0 | 09000064b92d9035 | ||||
| FWS-R5-FAC-2026-1684-0005 | FWS | Agency Information Collection Activities; Submission to the Office of Management and Budget; Horseshoe Crab and Cooperative Fish Tagging Programs FWS-R5-FAC-2026-1684 | FWS Form 3-2310 Horseshoe Crab Recapture Report Rev 07-2017 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:48:14Z | 0 | 0 | 09000064b92d9026 | ||||
| FWS-HQ-IA-2026-0298-0012 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Turtle Conservancy, Ojai, CA; Permit No. PER27229456 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:03Z | 0 | 0 | 09000064b92d95a2 | ||||
| FWS-HQ-IA-2026-0298-0008 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Vicki Lynn Lee, Ft. Collins, CO; Permit No. PER26618348 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:02Z | 0 | 0 | 09000064b92d9580 | ||||
| FWS-HQ-IA-2026-0298-0006 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Sam Noble Oklahoma Museum of Natural History, Norman, OK; Permit No. PER25540581 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:01Z | 0 | 0 | 09000064b92d957e | ||||
| FWS-HQ-IA-2026-0298-0004 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Charlie Dally, Rathdrum, ID; Permit No. PER27974123 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:00Z | 0 | 0 | 09000064b92d957c | ||||
| FWS-R5-FAC-2026-1684-0004 | FWS | Agency Information Collection Activities; Submission to the Office of Management and Budget; Horseshoe Crab and Cooperative Fish Tagging Programs FWS-R5-FAC-2026-1684 | FWS Form 3-2493 American Shad Recapture Data draft Rev 07-2017 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:48:12Z | 0 | 0 | 09000064b92d9025 | ||||
| FWS-HQ-IA-2026-0298-0013 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Henry Vilas Zoo, Madison, WI; Permit No. PER27541931 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:03Z | 0 | 0 | 09000064b92d95a3 | ||||
| FWS-HQ-IA-2026-0298-0007 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Brandon Isenhour, Hickory, NC; Permit No. PER26245660 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:01Z | 0 | 0 | 09000064b92d957f | ||||
| FWS-HQ-IA-2026-0298-0010 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Collin Griffiths, Missoula, MT; Permit No. PER26935891 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:02Z | 0 | 0 | 09000064b92d95a0 | ||||
| FWS-HQ-IA-2026-0298-0002 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Stephen Isenhour, Hickory, NC; Permit No. PER26245661 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:00Z | 0 | 0 | 09000064b92d957a | ||||
| FWS-R5-FAC-2026-1684-0001 | FWS | Agency Information Collection Activities; Submission to the Office of Management and Budget; Horseshoe Crab and Cooperative Fish Tagging Programs FWS-R5-FAC-2026-1684 | Agency Information Collection Activities; Submission to the Office of Management and Budget; Horseshoe Crab and Cooperative Fish Tagging Programs | Notice | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:47:48Z | 2026-09751 | 0 | 0 | 09000064b92da381 | |||
| FWS-HQ-IA-2026-0298-0005 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: Craig Keller, Tunkhannock, PA; Permit No. PER25338256 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:01Z | 0 | 0 | 09000064b92d957d | ||||
| FWS-HQ-IA-2026-1915-0001 | FWS | Agency Information Collection Activities; Submission to the Office of Management and Budget; Federal Fish and Wildlife Permit Applications and Reports—Management Authority FWS-HQ-IA-2026-1915 | Agency Information Collection Activities; Submission to the Office of Management and Budget; Federal Fish and Wildlife Permit Applications and Reports-Management Authority | Notice | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T16:50:38Z | 2026-09805 | 0 | 0 | 09000064b92da383 | ||
| FWS-HQ-IA-2026-0298-0011 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: St. Augustine Alligator Farm, St. Augustine, FL; Permit No. PER21244412 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:02Z | 0 | 0 | 09000064b92d95a1 | ||||
| FWS-HQ-IA-2026-0298-0009 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: St. Augustine Alligator Farm, St. Augustine, FL; Permit No. PER21244411 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:02Z | 0 | 0 | 09000064b92d9581 | ||||
| FWS-HQ-IA-2026-0298-0003 | FWS | Receipt of Application Minnesota Zoo, PER26188753 FWS-HQ-IA-2026-0298 | Applicant: George Sammut, Morgan Hill, CA; Permit No. PER26821388 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T16:54:00Z | 0 | 0 | 09000064b92d957b | ||||
| FDA-2025-P-6024-0008 | FDA | Requests that FDA declare that Clemastine Fumarate Oral Syrup, 0.25 mg base/5 mL, 0.75 mg base/5 mL, and 1 mg base/5 mL, is suitable for submission in an ANDA FDA-2025-P-6024 | Final Response | Other | Denial | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-16T01:50:33Z | 0 | 0 | 09000064b92dc6f6 | ||
| FDA-2026-H-5257-0001 | FDA | DAB Civil Money Penalty; Food Town Investments LLC d/b/a Food Town IGA FDA-2026-H-5257 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T23:01:41Z | 0 | 0 | 09000064b92dadf5 | ||
| FDA-2026-H-5256-0001 | FDA | DAB Civil Money Penalty; Mahadeva Inc. d/b/a Friendly Food Mart FDA-2026-H-5256 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T21:26:05Z | 0 | 0 | 09000064b92db9f3 | ||
| FDA-2025-N-0421-0002 | FDA | NOOH Proposal to Debar Oscar Bobo FDA-2025-N-0421 | Oscar Bobo: Final Debarment Order | Notice | Statutory Debarment | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T17:48:54Z | 2026-09767 | 1 | 0 | 09000064b92da9bd | |
| FDA-2026-H-5249-0001 | FDA | DAB Civil Money Penalty; Antler Lake Store & Motel, Inc., d/b/a Antler Lake Store & Motel FDA-2026-H-5249 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T18:10:17Z | 0 | 0 | 09000064b92da5b9 | ||
| FDA-2026-H-5251-0001 | FDA | DAB Civil Money Penalty; Chevron Stations Inc., d/b/a Chevron / Extra Mile FDA-2026-H-5251 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T18:18:45Z | 0 | 0 | 09000064b92da5f9 | ||
| FDA-2025-P-6262-0052 | FDA | Requests that FDA, under FDCA §505G(b) (OTC monograph administrative order process), amend OTC Monograph M013 to update Drug Facts labeling for all over-the-counter acetaminophen-containing products. In the alternative, Petitioner asks FDA to initiate such an order on its own FDA-2025-P-6262 | Interim Response | Other | Letter(s) | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T20:28:02Z | 0 | 0 | 09000064b92dbaa6 | ||
| FDA-2026-H-5248-0001 | FDA | DAB Civil Money Penalty; Prayosha Inc. of Live Oak, d/b/a Live Oak Liquors FDA-2026-H-5248 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T22:57:37Z | 0 | 0 | 09000064b92db36c | ||
| FDA-2026-H-5250-0001 | FDA | DAB Civil Money Penalty; Tornado 2 Tobacco and Vape Inc., d/b/a Tornado Tobacco & Vape FDA-2026-H-5250 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T21:35:08Z | 0 | 0 | 09000064b92dadef | ||
| FDA-2026-H-5255-0001 | FDA | DAB Civil Money Penalty; 6002 Gas Corp. d/b/a BP FDA-2026-H-5255 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T19:33:46Z | 0 | 0 | 09000064b92db377 | ||
| FDA-2026-H-5252-0001 | FDA | DAB Civil Money Penalty; Rudraunsh, Inc., d/b/a United Mart FDA-2026-H-5252 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T18:15:10Z | 0 | 0 | 09000064b92da5cd | ||
| FDA-2025-P-7006-0009 | FDA | Requests that FDA declare that Dicyclomine Hydrochloride Tablets, 10 mg, is suitable for submission as an ANDA FDA-2025-P-7006 | Final Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C. | Other | Grant of Petition | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T16:56:08Z | 0 | 0 | 09000064b92d515d | ||
| FDA-2026-H-5253-0001 | FDA | DAB Civil Money Penalty; Runlands LLC d/b/a Runland’s Grocery FDA-2026-H-5253 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T21:37:53Z | 0 | 0 | 09000064b92da628 | ||
| FDA-2026-H-5254-0001 | FDA | DAB Civil Money Penalty; Gondal Enterprises LLC, d/b/a Exxon FDA-2026-H-5254 | Complaint | Other | Complaint | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T19:53:37Z | 0 | 0 | 09000064b92da640 | ||
| FDA-2025-V-0353-0004 | FDA | Laser Light Show FDA-2025-V-0353 | Amendment to variance from Something Good | Other | Amendment | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T20:51:22Z | 0 | 0 | 09000064b92da646 | ||
| EPA-R01-SFUND-2026-0826-0005 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | FINAL PRE-REMEDIAL DESIGN INVESTIGATION REPORT | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:31Z | 0 | 0 | 09000064b92d8738 | ||||
| EPA-R01-SFUND-2026-0826-0009 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | ANNUAL REPORT FOR 2008 (03172010 TRANSMITTAL LETTER ATTACHED) | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:31Z | 0 | 0 | 09000064b92d873c | ||||
| EPA-R01-SFUND-2026-0826-0013 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | REDACTED FINAL 2024 ANNUAL REPORT | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:32Z | 0 | 0 | 09000064b92d874a | ||||
| EPA-R01-SFUND-2026-0826-0015 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | REDACTED FINAL 2010 ANNUAL REPORT - OPERABLE UNIT (OU) 1 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:32Z | 0 | 0 | 09000064b92d874c | ||||
| EPA-HQ-OW-2026-2575-0001 | EPA | Clean Water Act Section 312 Uniform National Discharge Standards Pre-Proposal Recommendations EPA-HQ-OW-2026-2575 | Memo Opening Docket for Comments | Other | Memorandum to Open a Docket | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-07-15T03:59:59Z | 2026-05-15T16:15:09Z | 1 | 0 | 09000064b92d6152 | |
| EPA-R01-SFUND-2026-0826-0002 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | FINAL PERMEABLE REACTIVE BARRIER CONCEPTUAL DESIGN REPORT | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:30Z | 0 | 0 | 09000064b92d8735 | ||||
| EPA-R01-SFUND-2026-0826-0012 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | REDACTED REMEDIAL INVESTIGATION (RI) REPORT ADDENDUM FOR TECHNICAL IMPRACTICABILITY (TI) ZONE BEDROCK | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:32Z | 0 | 0 | 09000064b92d8749 | ||||
| EPA-R01-SFUND-2026-0826-0004 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | FINAL FOCUSED FEASIBILITY STUDY (FFS) REPORT | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:30Z | 0 | 0 | 09000064b92d8737 | ||||
| EPA-R01-SFUND-2026-0826-0011 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | THIRD FIVE-YEAR REVIEW REPORT | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:32Z | 0 | 0 | 09000064b92d8748 | ||||
| EPA-R01-SFUND-2026-0826-0007 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | SAVAGE MUNICIPAL WATER SUPPLY OPERABLE UNIT (OU) 1 DRAFT THIRD EXPLANATION OF SIGNIFICANT DIFFERENCES (ESD) FOR P | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:31Z | 0 | 0 | 09000064b92d873a | ||||
| EPA-R01-SFUND-2026-0826-0008 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | DRAFT FINAL FOCUSED FEASIBILITY STUDY (FS) REPORT | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:31Z | 0 | 0 | 09000064b92d873b | ||||
| EPA-R01-SFUND-2026-0826-0010 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | ROOT CAUSE ANALYSIS AND MONITORIING NETWORK EVALUATION INSTALLATION OF DEEP BEDROCK MONITORING WELLS | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:32Z | 0 | 0 | 09000064b92d873d | ||||
| EPA-R01-SFUND-2026-0826-0003 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | FINAL TECHNICAL MEMORANDUM PROPOSED ALTERNATIVE REMEDY | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:30Z | 0 | 0 | 09000064b92d8736 | ||||
| EPA-HQ-OPPT-2018-0465-0072 | EPA | trans-1,2- Dichloroethylene; TSCA Review EPA-HQ-OPPT-2018-0465 | September 10, 2024 Amended Final Report TDCE Abiotic Feasibility Study submitted by BCCM | Supporting & Related Material | Report | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-16T01:40:23Z | 0 | 0 | 09000064b92d9dcf | |||
| EPA_FRDOC_0001-32815 | EPA | Recently Posted EPA Rules and Notices from FR Feed. EPA_FRDOC_0001 | Environmental Impact Statements; Availability, etc. | Notice | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T16:06:05Z | 2026-09788 | 0 | 0 | 09000064b92da963 | ||
| EPA-R01-SFUND-2026-0826-0006 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | FINAL 2025 ANNUAL REPORT | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:31Z | 0 | 0 | 09000064b92d8739 | ||||
| EPA-R01-SFUND-2026-0826-0014 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | REDACTED 2020 ANNUAL REPORT - OPERABLE UNIT (OU) 1 | Supporting & Related Material | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T17:14:32Z | 0 | 0 | 09000064b92d874b | ||||
| EPA-R01-SFUND-2026-0826-0001 | EPA | Savage Municipal OU1 Draft Explanation of Significant Differences (ESD) EPA-R01-SFUND-2026-0826 | DRAFT THIRD EXPLANATION OF SIGNIFICANT DIFFERENCES (ESD) - OPERABLE UNIT (OU) 1 FOR PUBLIC COMMENT | Notice | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-31T03:59:59Z | 2026-05-15T17:14:22Z | 1 | 0 | 09000064b92d8fff | ||
| USDA_FRDOC_0001-3306 | USDA | Recently Posted USDA Rules and Notices. USDA_FRDOC_0001 | Agency Information Collection Activities; Proposals, Submissions, and Approvals | Notice | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T16:26:14Z | 2026-09645 | 0 | 0 | 09000064b92d8201 | ||
| FDA-2026-P-5578-0003 | FDA | Requests that the FDA declare that an ANDA may be submitted for, Tranexamic Acid Tablets, USP 1300 mg a strength that differs from the currently approved RLD, LYSTEDA (Tranexamic Acid) tablets from AMRING PHARMACEUTICALS INC., which FDA approved in 650 mg strength prior to Nov, 13th 2009 under NDA #022430. FDA-2026-P-5578 | Attachment 1 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T23:18:06Z | 0 | 0 | 09000064b92d70f0 | |||
| FDA-2026-P-5611-0001 | FDA | Request that the FDA determine and declare that Gabapentin Tablets 150 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-5611 | Suitability Petition from Senores Pharmaceuticals, Inc | Other | Petition(s) | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T23:37:18Z | 1 | 0 | 09000064b92d9592 | ||
| FDA-2026-P-5454-0016 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 14 - Andreasen, S. M., et al. (2025). Maternal urinary paracetamol concentrations and self-reported paracetamol use in mid-gestation: association to reduced anogenital distance in offspring from infancy to 9 years. Reproductive Toxicology, 135, 108946. URL: https://pubmed.ncbi.nlm.nih.gov/40374128/ | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:43:22Z | 0 | 0 | 09000064b92d5033 | |||
| FDA-2026-P-5454-0012 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 10 - Liu, F., et al. (2024). Maternal administration of acetaminophen affects meiosis through its metabolite NAPQI targeting SIRT7 in fetal oocytes. Antioxidants & Redox Signaling, 41, 93-109. URL: https://doi.org/10.1089/ars.2023.0270 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:50Z | 0 | 0 | 09000064b92d502f | |||
| FDA-2026-P-5454-0008 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | References 6 - Lecante, L. L., et al. (2022). Acetaminophen interferes with the first trimester human fetal ovary development in an ex vivo model. Journal of Clinical Endocrinology & Metabolism, 107(6), 1647-1661. URL: https://pubmed.ncbi.nlm.nih.gov/35147701/ | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:35Z | 0 | 0 | 09000064b92d5010 | |||
| FDA-2026-P-5454-0019 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 17 - Zafeiri, A., et al. (2022). Maternal over-the-counter analgesics use during pregnancy and adverse perinatal outcomes: cohort study of 151,141 singleton pregnancies. BMJ Open, 12(5), e048092. URL: https://doi.org/10.1136/bmjopen-2020-048092 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:43:32Z | 0 | 0 | 09000064b92d5036 | |||
| FDA-2026-P-5454-0010 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | References 8 - Nielsen, B. S., et al. (2025). Paracetamol disrupts early embryogenesis by cell cycle inhibition. Human Reproduction, 40(10), 1860-1876. URL: https://doi.org/10.1093/humrep/deaf116 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:42Z | 0 | 0 | 09000064b92d5012 | |||
| FDA-2026-P-5454-0022 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 20 - Kougias, D. G., et al. (2025). A quantitative weight-of-evidence review of preclinical studies examining the potential developmental and reproductive toxicity of acetaminophen. Critical Reviews in Toxicology, 55(2), 179-226. URL: https://doi.org/10.1080/10408444.2024.2446471 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:43:58Z | 0 | 0 | 09000064b92d5039 | |||
| FDA-2026-P-3630-0006 | FDA | Requests that the FDA issue a declaration permitting the submission of an Abbreviated New Drug Application (ANDA) for Tamsulosin Hydrochloride Capsules, USP 0.8 mg FDA-2026-P-3630 | Completeness Assessment Correspondence | Other | Assessment Document or Analysis | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T15:19:06Z | 0 | 0 | 09000064b92d613f | ||
| FDA-2026-P-5611-0002 | FDA | Request that the FDA determine and declare that Gabapentin Tablets 150 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-5611 | Acknowledgment Letter from FDA DMB to Senores Pharmaceuticals, Inc | Other | Acknowledgement Letter/Receipt | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T23:37:28Z | 0 | 0 | 09000064b92d7cce | ||
| FDA-2026-P-5454-0020 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 18 - Rehfeld, A., et al. (2022). Human sperm cells can form paracetamol metabolite AM404 that directly interferes with sperm calcium signalling and function through a CatSper-dependent mechanism. Human Reproduction, 37(5), 922-935. URL: https://doi.org/10.1093/humrep/deac042 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:43:48Z | 0 | 0 | 09000064b92d5037 | |||
| FDA-2026-P-5454-0023 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 21 - OFIRMEV (acetaminophen) Injection Package Insert. (2018). Mallinckrodt Hospital Products Inc. | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:44:02Z | 0 | 0 | 09000064b92d503a | |||
| FDA-2026-P-5454-0018 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 16 - Xu, M., et al. (2024). Association of acetaminophen use with perinatal outcomes among pregnant women: a retrospective cohort study with propensity score matching. BMC Pregnancy and Childbirth, 24, 268. URL: https://doi.org/10.1186/s12884-024-06480-5 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:43:29Z | 0 | 0 | 09000064b92d5035 | |||
| FDA-2026-P-5454-0005 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 3 - Lind, D. V., et al. (2017). Maternal use of mild analgesics during pregnancy associated with reduced anogenital distance in sons. Human Reproduction, 32(1), 149-155. URL: https://pubmed.ncbi.nlm.nih.gov/27852690/ | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:12Z | 0 | 0 | 09000064b92d500d | |||
| FDA-2026-P-5611-0005 | FDA | Request that the FDA determine and declare that Gabapentin Tablets 150 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-5611 | attachment-3-test-product-draft-labeling | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T23:38:07Z | 0 | 0 | 09000064b92d8751 | |||
| FDA-2026-P-5611-0004 | FDA | Request that the FDA determine and declare that Gabapentin Tablets 150 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-5611 | attachment-2-rld-labeling | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T23:38:03Z | 0 | 0 | 09000064b92d8750 | |||
| FDA-2026-P-5578-0002 | FDA | Requests that the FDA declare that an ANDA may be submitted for, Tranexamic Acid Tablets, USP 1300 mg a strength that differs from the currently approved RLD, LYSTEDA (Tranexamic Acid) tablets from AMRING PHARMACEUTICALS INC., which FDA approved in 650 mg strength prior to Nov, 13th 2009 under NDA #022430. FDA-2026-P-5578 | Acknowledgement Letter from FDA DMB to Appco Pharma LLC | Other | Acknowledgement Letter/Receipt | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T23:17:57Z | 0 | 0 | 09000064b92d8f63 | ||
| FDA-2026-P-5454-0007 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | References 5 - Górawski, F., et al. (2026). Sex-dependent effects of early-life paracetamol exposure on behavior and monoamines in the rat central nervous system. Chemico-Biological Interactions, 427, 111937. URL: https://doi.org/10.1016/j.cbi.2026.111937 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:31Z | 0 | 0 | 09000064b92d500f | |||
| FDA-2026-P-5454-0006 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | References 4 - Guzmán-Montemayor, A. J., et al. (2026). Prenatal, but not neonatal, paracetamol exposure disrupts neuroendocrine regulation of stress and emotional behavior in adult male rats. Physiology & Behavior, 308, 115261. URL: https://doi.org/10.1016/j.physbeh.2026.115261 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:16Z | 0 | 0 | 09000064b92d500e | |||
| FDA-2026-P-5454-0003 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | References 1 - Ernstsen, C., et al. (2026). Prenatal paracetamol modulates sexually dimorphic behaviour and steroidogenesis in adult male and female mice. Reproduction, 171(2). URL: https://doi.org/10.1093/reprod/xaag007 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:41:54Z | 0 | 0 | 09000064b92d500b | |||
| FDA-2026-P-5454-0021 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 19 - Eletri, L., et al. (2026). Association between in utero exposure to acetaminophen and external genital tract malformations in boys and girls: a systematic review and meta-analysis. Human Reproduction, 41(3), 427-442. URL: https://doi.org/10.1093/humrep/deaf253 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:43:53Z | 0 | 0 | 09000064b92d5038 | |||
| FDA-2026-P-5611-0003 | FDA | Request that the FDA determine and declare that Gabapentin Tablets 150 mg is suitable for submission in an Abbreviated New Drug Application (ANDA) FDA-2026-P-5611 | attachment-1-orange-book-page | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T23:37:59Z | 0 | 0 | 09000064b92d874f | |||
| FDA-2026-P-5454-0017 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 15 - Lee, C. Y., et al. (2023). Effects of acetaminophen on reproductive activities in male golden hamsters. Development & Reproduction, 27(1), 25-37. URL: https://doi.org/10.12717/DR.2023.27.1.25 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:43:26Z | 0 | 0 | 09000064b92d5034 | |||
| FDA-2020-V-0476-0004 | FDA | Laser Light Show FDA-2020-V-0476 | Variance Renewal Application from Andrew Stuart | Other | Application for Variance (VAR) | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T18:05:51Z | 0 | 0 | 09000064b92d76f8 | ||
| FDA-2026-H-5191-0001 | FDA | DAB Civil Money Penalty; Nafii Group LLC d/b/a Morning Star Market / Marathon FDA-2026-H-5191 | Complaint | Other | Complaint | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T20:05:30Z | 0 | 0 | 09000064b92d6cee | ||
| FDA-2026-H-5184-0001 | FDA | DAB Civil Money Penalty; Tobacco Zone Inc., d/b/a Tobacco Zone FDA-2026-H-5184 | Complaint | Other | Complaint | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T19:33:28Z | 0 | 0 | 09000064b92d6ce9 | ||
| FDA-2026-P-5578-0005 | FDA | Requests that the FDA declare that an ANDA may be submitted for, Tranexamic Acid Tablets, USP 1300 mg a strength that differs from the currently approved RLD, LYSTEDA (Tranexamic Acid) tablets from AMRING PHARMACEUTICALS INC., which FDA approved in 650 mg strength prior to Nov, 13th 2009 under NDA #022430. FDA-2026-P-5578 | Attachment 3 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T23:18:14Z | 0 | 0 | 09000064b92d70f2 | |||
| FDA-2026-P-5578-0004 | FDA | Requests that the FDA declare that an ANDA may be submitted for, Tranexamic Acid Tablets, USP 1300 mg a strength that differs from the currently approved RLD, LYSTEDA (Tranexamic Acid) tablets from AMRING PHARMACEUTICALS INC., which FDA approved in 650 mg strength prior to Nov, 13th 2009 under NDA #022430. FDA-2026-P-5578 | Attachment 2 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T23:18:09Z | 0 | 0 | 09000064b92d70f1 | |||
| FDA-2026-H-5193-0001 | FDA | DAB Civil Money Penalty; Semo Gas Stations LLC d/b/a Cooter Browns / Exxon FDA-2026-H-5193 | Complaint | Other | Complaint | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-15T00:35:04Z | 0 | 0 | 09000064b92d79e2 | ||
| FDA-2026-P-5578-0001 | FDA | Requests that the FDA declare that an ANDA may be submitted for, Tranexamic Acid Tablets, USP 1300 mg a strength that differs from the currently approved RLD, LYSTEDA (Tranexamic Acid) tablets from AMRING PHARMACEUTICALS INC., which FDA approved in 650 mg strength prior to Nov, 13th 2009 under NDA #022430. FDA-2026-P-5578 | Suitability Petition from Appco Pharma LLC | Other | Petition(s) | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T23:17:53Z | 1 | 0 | 09000064b92d8f5b | ||
| FDA-2026-P-5454-0013 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 11 - Wu, T., et al. (2024). Prenatal acetaminophen exposure and the developing ovary: time, dose, and course consequences for fetal mice. Food and Chemical Toxicology, 189, 114679. URL: https://doi.org/10.1016/j.fct.2024.114679 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:53Z | 0 | 0 | 09000064b92d5030 | |||
| FDA-2026-P-5454-0004 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | References 2 - Fisher, B. G., et al. (2016). Prenatal paracetamol exposure is associated with shorter anogenital distance in male infants. Human Reproduction, 31(11), 2642-2650. URL: https://pubmed.ncbi.nlm.nih.gov/27609981/ | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:41:58Z | 0 | 0 | 09000064b92d500c | |||
| FDA-2026-P-5454-0011 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 9 - Carlsen, L. N., et al. (2024). Overuse of analgesics can affect the fertility biomarker Anti-Müllerian Hormone in females. A translational study. Cephalalgia, 44(11). URL: https://doi.org/10.1177/03331024241290530 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:46Z | 0 | 0 | 09000064b92d5013 | |||
| FDA-2025-P-6350-0004 | FDA | Requests that the FDA initiate notice-and-comment rulemaking to amend 21 CFR § 1271.90 to extend the existing regulatory exception for surplus cryopreserved embryos to surplus cryopreserved oocytes originally recovered for a woman’s own reproductive use FDA-2025-P-6350 | Interim Response Letter from FDA CBER to Jack Weis | Other | Response(s) | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T18:12:30Z | 0 | 0 | 09000064b92d7d0a | ||
| FDA-2026-P-5454-0001 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Citizen Petition from Americans for Scientific Integrity | Other | Citizen Petition | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T17:41:38Z | 1 | 0 | 09000064b92d4fe7 | ||
| FDA-2026-P-5454-0002 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Acknowledgment Letter from FDA DMB to Americans for Scientific Integrity | Other | Acknowledgement Letter/Receipt | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T17:41:43Z | 0 | 0 | 09000064b92d4fe9 | ||
| FDA-2022-V-0385-0004 | FDA | Laser Light Show FDA-2022-V-0385 | Variance Renewal Application from Brant Parrish | Other | Application for Variance (VAR) | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T04:00:00Z | 2026-05-14T18:02:11Z | 0 | 0 | 09000064b92d6cc8 | ||
| FDA-2026-P-5454-0015 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 13 - Laursen, T. Q., et al. (2024). Maternal intake of paracetamol during pregnancy and biomarkers of male fecundity in young adult sons. Reproductive Toxicology, 127, 108626. URL: https://doi.org/10.1016/j.reprotox.2024.108626 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:43:00Z | 0 | 0 | 09000064b92d5032 | |||
| FDA-2026-P-5454-0014 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | Reference 12 - de Araújo-Ramos, A. T., et al. (2026). Differential disruption of gonadal development by DEHP and paracetamol in male and female Wistar rats. Reproductive Toxicology, 141, 109183. URL: https://doi.org/10.1016/j.reprotox.2026.109183 | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:56Z | 0 | 0 | 09000064b92d5031 | |||
| FDA-2026-P-5454-0009 | FDA | Request that the FDA take action to amend OTC acetaminophen labeling regarding reproductive toxicity, fertility impairment, and developmental endocrine disruption FDA-2026-P-5454 | References 7 - Smarr, M. M., et al. (2016). Urinary paracetamol and time-to-pregnancy. Human Reproduction, 31(9), 2119-2127. URL: https://pubmed.ncbi.nlm.nih.gov/27412248/ | Supporting & Related Material | Background Material | 2026-05-14T04:00:00Z | 2026 | 5 | 2026-05-14T17:42:39Z | 0 | 0 | 09000064b92d5011 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;